AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00858195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocin 75mg SR Capsules
Study NCT03339037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: 60 HBOT sessions at 2 ATA 100% oxygen
Study NCT03339037 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normobaric air SHAM
Description: 60 sessions at 1 ATA 21% oxygen (air)
Study NCT00581620 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcus conjugate vaccine
Description: Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
Study NCT03377959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ballet Classes
Description: The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
Study NCT03377959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballet Classes
Description: The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
Study NCT03594266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components
Description: Therapy A stimulation patterns
Study NCT02401464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Dry Syrup Formulation
Description: TAK-536 dry syrup formulation
Study NCT02401464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Ganule Formulation
Description: TAK-536 granule formulation
Study NCT03145766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 2
Description: Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free
Study NCT03145766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 1
Description: Initial formulation of Purified Vero Rabies Vaccine Serum Free
Study NCT03145766 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax Rabies
Description: Purified inactivated rabies vaccine prepared on human diploid cell cultures
Study NCT03145766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 2
Description: Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free
Study NCT03145766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 2
Description: Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free
Study NCT03145766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rabies Immunoglobulins (HRIG)
Description: Commercialized formulation of HRIG
Study NCT03145766 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rabies Immunoglobulins (HRIG)
Description: Commercialized formulation of HRIG
Study NCT03850080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Conditioned Serum
Description: Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA.
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir (MK7009)
Description: vaniprevir 300 mg soft gel capsules twice daily.
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: vaniprevir (MK7009)
Description: vaniprevir 600 mg soft gel capsules twice daily.
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to vaniprevir
Description: Placebo to vaniprevir soft gel capsules twice daily.
Study NCT00895882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to vaniprevir
Description: Placebo to vaniprevir soft gel capsules twice daily.
Study NCT00745706 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Loop Recorder (ILR)
Description: Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
Study NCT03818789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance training
Description: A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
Study NCT03818789 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Study skills video
Description: A YouTube video describing study skills and suggested habits is used as a control condition.
Study NCT03161457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1101
Description: 1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
Study NCT03161457 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: 1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
Study NCT03381404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] MT-8554
Description: 14-C MT-8554
Study NCT01724645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean traditional diets
Description: The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.
Study NCT01724645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Told to  eat as usal diets.
Study NCT03158363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS, 36 hour immobilization and fast
Description: LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
Study NCT03199157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl transdermal patch
Description: Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
Study NCT04389879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer
Description: Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
Study NCT04389879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer
Description: Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
Study NCT02264951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tributyrin
Description: a triglyceride containing three C4-acids
Study NCT02264951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C8-diet oil
Description: a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
Study NCT02264951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: a triglyceride containing mostly three oleic acids
Study NCT02264951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carrot
Description: mainly water and glucose
Study NCT02264951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrot
Description: mainly water and glucose
Study NCT01543100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and bone marrow samples
Description: Specific tests of the study will be realized from :~* Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~* Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed.
Study NCT01127009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01127009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT01127009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01127009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01127009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT02222766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Tots Together Program
Description: Group-based parenting program, 9 sessions offered weekly
Study NCT02222766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Minimal attention control- 9 weekly mailed information on general child development
Study NCT05719948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flouroscopic guidance cervical medial branch radiofrequency ablation
Description: Electromagnetic wave deposition near nerve tissue for pain management
Study NCT03594266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components
Description: Therapy B stimulation patterns
Study NCT02284802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Description: Confocal endomicroscopy examination during endoscopy
Study NCT00719238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition plus education
Description: Nutritional instruction in small groups plus education
Study NCT00719238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: Educational video and pamphlets
Study NCT01421186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR03087 phase 1 dose escalation
Description: Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.~In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.
Study NCT01421186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR03087
Description: MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
Study NCT01421186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
Study NCT01421186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
Study NCT01421186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
Study NCT01933035 — intervention group
Intervention type: OTHER
Intervention: Immune Thrombocytopenics
Description: Full blood count with extended platelet parameters
Study NCT01933035 — intervention group
Intervention type: OTHER
Intervention: Hypo-proliferative thrombocytopenics
Description: Full blood count with extended platelet parameters
Study NCT02338219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum female pelvic floor muscle affection
Description: transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.
Study NCT02338219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum sexual function in Egyptian women.
Description: answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
Study NCT01062542 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw and Ultrasound
Description: Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
Study NCT03277469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
Study NCT03277469 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Radiation therapy that is delivered by inserting radioactive sources directly into a tumor
Study NCT03277469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Tracker
Description: The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
Study NCT04801147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells Vaccine
Description: Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient.
Study NCT02070016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study NCT04523103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Assisted Activation
Description: Artificial assisted activation represents an effective technique to rescue the fertilization failure.
Study NCT01933035 — intervention group
Intervention type: OTHER
Intervention: Control Population
Description: Full blood count with extended platelet parameters
Study NCT00944723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc-fortified bread
Description: Bread made with zinc-fortified wheat flour
Study NCT01363245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Telephone counseling: 7 calls over 6 weeks
Study NCT01363245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fax-to-quit
Description: referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
Study NCT00883467 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: preconditioning
Description: 3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
Study NCT00883467 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: no preconditioning
Description: no preconditioning
Study NCT00944723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Description: Liquid supplement with zinc
Study NCT00944723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified bread
Description: Daily consumption of non-fortified bread
Study NCT00944723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-fortified bread
Description: Daily consumption of non-fortified bread
Study NCT00944723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Daily intake of placebo supplement
Study NCT00944723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Description: Daily intake of placebo supplement
Study NCT04358276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Complete online course
Study NCT04358276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatoscope
Description: Receive dermatoscope
Study NCT04358276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive study packet
Study NCT04358276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (Physician)
Description: Receive physician directed letter and educational package
Study NCT04358276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04358276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages
Study NCT02465502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
Study NCT02274870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Bupivacaine
Description: Administered via local tissue infiltration around the knee joint
Study NCT02274870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Administered via CFNB
Study NCT04121065 — intervention group
Intervention type: PROCEDURE
Intervention: Blood withdrawal
Description: Blood withdrawal of maximum 60 ml performed to each enrolled patient during the study for primary and secondary endpoints evaluation.
Study NCT01455272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic GPBPCI
Description: A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
Study NCT00845208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Network Support
Description: 12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
Study NCT00845208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network Support
Description: 12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
Study NCT02372812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 12 mg of dexamethasone
Study NCT02372812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02255513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200
Study NCT00823043 — intervention group
Intervention type: DRUG
Intervention: timolol hemihydrate
Description: timolol hemihydrate 0.5% solution
Study NCT02255513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01485536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
Study NCT00823043 — intervention group
Intervention type: DRUG
Intervention: timolol maleate
Description: timolol maleate in sorbate